Innovent Biologics

Biologics & Biosimilars · Oncology Therapeutics
290Open roles
Data updated Nov 22, 2026Full reportReport a mistake

Facts

as of Nov 22, 2026

Innovent Biologics is a Chinese biopharmaceutical company headquartered in Suzhou, Jiangsu, that discovers, develops, manufactures and sells medicines for cancer, metabolic, autoimmune and other serious diseases. Founded in 2011 and listed in Hong Kong, it markets the PD-1 antibody sintilimab under the Tyvyt brand and co-develops the GLP-1 and glucagon receptor agonist mazdutide with Eli Lilly, with research and commercial teams across Suzhou, Shanghai, Hangzhou and Beijing. It hires medicinal chemistry and DMPK leaders, CMC development researchers, medical science liaisons, clinical research associates, regional marketing managers and information security engineers.

It is hiring: 290 open roles, 0 of them posted in the last 30 days.

Headquarters
Suzhou, China
Founded
2011
Employees
1001-5000estimated range
Open roles
290 in 28 citiesAlion job postings

As of Nov 22, 2026, Alion lists 290 open roles at Innovent Biologics. Innovent Biologics is headquartered in Suzhou, China. It was founded in 2011.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

290 open roles, 0 of them posted in the last 30 days.

290Open roles
Where the openings areshare of open roles
Marketing23%▼
Biotech17%▲
Management10%▲
Engineering10%▼
HR8%▲
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family

Products

Wikipedia readersen.wikipedia.org
Nov 2025Oct 2026 · 372

Innovent Biologics: 198 research papers in five years.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Milestones

Jul 4, 2025
2011
Founded
Each milestone is dated by its source: registers, filings, the press